6 September 2017
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
An application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 174,000 ordinary shares of 1 pence each (the "Shares") to be admitted to the Official List.
These Shares are being reserved under a block listing and will be issued pursuant to the following scheme:
Long Term Incentive Plan (LTIP)
These Shares will rank pari passu with the Company's existing shares in issue. It is expected that admission will become effective on 8 September 2017.
For further information
For further information, please contact:
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Telephone number: +44 (00 1606 814730
Email: [email protected]
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS